Iovance Biotherp Stock Price, News & Analysis

Iovance Biotherapeutics has appointed Igor Bilinsky, Ph.D., as Chief Operating Officer, effective immediately. Dr. Bilinsky brings over 20 years of experience in biotechnology, including senior roles at Oncternal Therapeutics and AmpliPhi Biosciences. His expertise in operational leadership and manufacturing is expected to enhance Iovance’s TIL cell therapy pipeline and potential commercialization. Iovance focuses on T cell-based therapies for cancer treatment, including pivotal studies in melanoma and cervical cancer.

Iovance Biotherapeutics (NASDAQ: IOVA) has announced that long-term interim data from Cohort 2 of the C-144-01 clinical study in advanced melanoma will be presented at the AACR 2021 Annual Meeting. The presentation will focus on the efficacy of Lifileucel (LN-144), a T cell-based therapy, showing durable responses at 28-month follow-up. In addition to this oral presentation, three poster presentations will elaborate on ongoing clinical trials in solid tumors and chronic lymphocytic leukemia. The AACR meeting takes place virtually on April 10, 2021.

Iovance Biotherapeutics has announced upcoming presentations at various virtual healthcare conferences. Key events include the Cowen 41st Annual Health Care Conference on March 3 at 1:20 p.m. ET, H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 a.m. ET, Barclays Global Healthcare Conference on March 11 at 1:50 p.m. ET, and Oppenheimer 31st Annual Healthcare Conference on March 17 at 1:10 p.m. ET. The webcasts of these presentations will be available on the Iovance website.

Iovance Biotherapeutics (NASDAQ: IOVA) reported its Q4 and full-year 2020 financial results, showing a cash position of $635 million, expected to last into 2023. The company emphasized progress in its TIL cell therapies across various cancers, including melanoma and cervical cancer, and plans for a potential BLA submission in 2021. R&D expenses rose to $201.7 million for the year, while general and administrative expenses increased to $60.2 million. The net loss for Q4 was $68.4 million, with a full-year net loss of $259.6 million.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) will release its fourth quarter and full year 2020 financial results on February 25, 2021. A conference call will follow at 4:30 p.m. EST to discuss these results. The company focuses on T cell-based cancer immunotherapies, having completed pivotal programs for metastatic melanoma and cervical cancer. Iovance is also investigating tumor infiltrating lymphocyte (TIL) therapy for non-small cell lung cancer and earlier-stage cancers. For further information, visit www.iovance.com.

Iovance Biotherapeutics (NASDAQ: IOVA) announced participation in three upcoming virtual healthcare conferences to discuss advancements in T cell-based cancer therapies. The sessions include:

• B. Riley Oncology Investor Conference: January 20, 2021, at 1:00 p.m. ET.
• Guggenheim Healthcare Talks Oncology Days: February 11, 2021, at 12:00 p.m. ET.
• 7th Annual Immuno-Oncology 360° Conference: Panel on February 23, 2021, at 11:10 a.m. ET, followed by a presentation on TIL therapy at 1:45 p.m. ET.

Webcasts will be available on Iovance's Investor website.

Iovance Biotherapeutics, a late-stage biotechnology company, has announced that its CEO, Maria Fardis, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 10:50 a.m. ET. Iovance is focused on T cell-based cancer immunotherapies, particularly tumor-infiltrating lymphocyte (TIL) therapy, which utilizes a patient's own immune cells to combat cancer. The company has completed dosing in pivotal studies for metastatic melanoma and cervical cancer. Further, Iovance's therapies are exploring treatment for various advanced cancers.

Iovance Biotherapeutics (NASDAQ: IOVA) has appointed Jean-Marc Bellemin as Chief Financial Officer, a move aimed at enhancing the company's strategic financial oversight. Bellemin brings 27 years of experience, including significant roles in public biopharma companies. His previous positions include CFO at Gritstone Oncology and Actelion Pharmaceuticals, where he contributed to substantial revenue growth and multiple product launches. The appointment is timely as Iovance transitions toward commercializing TIL cell therapy for cancer treatment, with ongoing clinical studies in advanced stages.

Iovance Biotherapeutics, a late-stage biotechnology firm focused on T cell-based cancer immunotherapies, announced presentations at key conferences from December 1-3, 2020. Events include the Piper Sandler 32nd Annual Virtual Healthcare Conference, and the Cellular Immunotherapies for Solid Tumors Summit, where they will discuss the clinical success of their TIL technology. The company is advancing TIL therapy for various cancers, including metastatic melanoma and cervical cancer. Webcasts of the presentations will be available on their website.